Overview

The EPA commissioned The National Academies to provide advice on the vexing question of whether and, if so, under what circumstances EPA should accept and consider intentional human dosing studies conducted by companies or other sources outside the agency (so-called third parties) to gather evidence relating to the risks of a chemical or the conditions under which exposure to it could be judged safe. This report recommends that such studies be conducted and used for regulatory purposes only if all of several strict conditions are met, including the following: * The study is necessary and scientifically valid, meaning that it addresses an important regulatory question that cana (TM)t be answered with animal studies or nondosing human studies; * The societal benefits of the study outweigh any anticipated risks to participants. At no time, even when benefits beyond improved regulation exist, can a human dosing study be justified that is anticipated to cause lasting harm to study participants; and * All recognized ethical standards and procedures for protecting the interests of study participants are observed. * In addition, EPA should establish a Human Studies Review Board (HSRB) to evaluate all human dosing studies a "" both at the beginning and upon completion of the experiments a "" if they are carried out with the intent of affecting the agency's policy-making.

Full Product Details

Author:   Committee on the Use of Third Party Toxicity Research with Human Research Participants Science, Technology, and Law Program ,  Policy and Global Affairs ,  National Research Council ,  National Academy of Sciences
Publisher:   National Academies Press
Imprint:   National Academies Press
ISBN:  

9780309091725

ISBN 10:   0309091721
Pages:   226
Publication Date:   04 July 2004
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

1 Front Matter; 2 Executive Summary and Recommendations; 3 1 Introduction and Background; 4 2 The Regulatory Framework for Protecting Humans in Research; 5 3 Scientific Justification for and Conduct of Intentional Human Dosing Studies; 6 4 A Risk-Benefit Framework for Assessing Intentional Human Dosing Studies; 7 5 Ethical Considerations in the Review of Intentional Human Dosing Studies; 8 6 Procedures for EPA Review of Intentional Human Dosing Studies; 9 7 EPA's Use of Data from Intentional Human Dosing Studies in Risk Assessment; 10 Appendix A: Values and Limitations of Animal Toxicity Data; 11 Appendix B: Pharmacokinetics and Metabolism of Pesticides; 12 Appendix C: Biographical Sketches of the Members and Staff of the Committee on the Use of Third Party Toxicity Research with Human Research Participants; 13 Appendix D: Biographical Sketches of the Members of the Science, Technology, and Law Panel; 14 Appendix E: Meeting Agendas; 15 Appendix F: Combined Registrants List for All Meetings

Reviews

Author Information

Committee on the Use of Third Party Toxicity Research with Human Research Participants Science, Technology, and Law Program, National Research Council

Tab Content 6

Author Website:  

Countries Available

All regions